What is the appropriate management for a patient with gastroesophageal junction (GEJ) narrowing observed on esophagogastroduodenoscopy (EGD)?

Management of Gastroesophageal Junction (GEJ) Narrowing on EGD

The immediate priority is to determine whether the GEJ narrowing is malignant or benign through tissue biopsy during EGD, followed by cross-sectional imaging if malignancy is suspected, as this fundamentally determines all subsequent management decisions.

Initial Diagnostic Approach

When EGD reveals GEJ narrowing, you must first establish the etiology:

Obtain Biopsies During EGD

• Take multiple biopsies from the narrowed area to rule out malignancy (gastric adenocarcinoma, esophageal cancer)
• Older patients with rapid-onset dysphagia, weight loss, or systemic symptoms require heightened suspicion for pseudoachalasia from malignancy 1
• Diffuse-type gastric adenocarcinoma can infiltrate the GEJ and mimic achalasia

Consider Additional Diagnostic Testing

• Timed barium esophagram (TBE): Useful to assess functional significance of the narrowing and distinguish true obstruction from manometric artifact 2, 3
• High-resolution esophageal manometry: If functional disorder (EGJOO, achalasia) is suspected based on clinical presentation
• Functional lumen imaging probe (FLIP): Confirms clinically relevant obstruction when manometry shows elevated integrated residual pressure 2, 3

Important caveat: CT chest/abdomen and EUS are frequently unhelpful in determining the cause of GEJ narrowing when endoscopy is unrevealing. Studies show these tests provided no useful information in the vast majority of EGJOO cases 4. Reserve cross-sectional imaging specifically for cases where malignancy is suspected based on endoscopic appearance or biopsy results.

Management Based on Etiology

If Malignant Obstruction is Confirmed

For patients who are potential surgical candidates or candidates for chemoradiation:

• Do NOT routinely place a self-expanding metal stent (SEMS) without multidisciplinary review 5
• SEMS placement is associated with high migration rates, increased morbidity/mortality, and potentially lower R0 resection rates
• Consider enteral feeding tubes (nasogastric or percutaneous) if malnutrition is a concern, though be aware of potential tumor seeding risk with PEG placement 5

For patients who are NOT candidates for resection:

• Use fully covered or partially covered SEMS (not uncovered) with consideration of stent-anchoring methods to reduce migration 5
• Alternative: brachytherapy as sole therapy or in combination with SEMS 5
• Avoid laser therapy or photodynamic therapy due to lack of evidence for better outcomes 5

For malignant gastric outlet obstruction at the GEJ:

• Life expectancy >2 months + good functional status + surgically fit: Surgical gastrojejunostomy (laparoscopic approach preferred) 5
• Not surgical candidates: Enteral stent placement 5
• EUS-guided gastroenterostomy: Acceptable alternative at experienced centers, though no FDA-approved dedicated devices currently exist 5

If Benign Stricture (Peptic, Post-Surgical, or Other)

Endoscopic dilation is the primary treatment:

• Use wire-guided balloon or bougie dilators under direct visualization 6
• For very narrow strictures: limit initial dilation to 10-12 mm diameter (30-36F) 6
• Use no more than three successively larger diameter increments per session 6
• Perform weekly or two-weekly sessions until easy passage of ≥15 mm dilator is achieved with symptomatic improvement 6

Critical adjunctive therapy:

• High-dose PPI therapy is mandatory for peptic strictures to reduce recurrence 6
• PPIs are more effective than H2 receptor antagonists for preventing stricture recurrence 6
• Continue PPI therapy long-term after dilation 6

For refractory strictures (requiring >5 dilations to achieve symptom relief or inability to maintain patency for 4 weeks):

• Ensure optimal PPI therapy before defining as refractory 6
• Intralesional steroid injection combined with dilation for strictures with ongoing inflammation 6
• Temporary fully covered removable stent placement (4-8 weeks) if other methods unsuccessful 6
• Surgery for patients who don't respond to endoscopic measures 6

If Functional Disorder (EGJOO/Achalasia Pattern)

Rule out secondary causes first:

• Opioid medications are a common reversible cause 3
• Mechanical obstruction must be excluded

For confirmed clinically relevant EGJOO (elevated IRP in supine AND upright positions + obstructive symptoms + confirmatory TBE or FLIP):

• Expectant management for mild or atypical symptoms - many improve without intervention 3, 4
• Botulinum toxin injection: Limited durability but useful to predict response before definitive treatment 3
• Pneumatic dilation or peroral endoscopic myotomy (POEM): Effective for confirmed EGJOO 2, 3
• Heller myotomy may be considered but data for confirmed EGJOO is limited 2

Post-treatment considerations:

• PPI therapy after any LES-directed intervention due to 10-40% rate of symptomatic GERD 6
• Monitor for progression to achalasia, though this occurs in only a small minority of cases 4

Common Pitfalls to Avoid

1. Do not assume benign etiology in older patients with rapid-onset symptoms and red flags - always biopsy 1
2. Do not order CT or EUS reflexively for GEJ narrowing - they are rarely helpful unless malignancy is suspected on endoscopy 4
3. Do not place SEMS in potentially resectable malignancy without multidisciplinary discussion 5
4. Do not perform dilation without adequate PPI therapy for peptic strictures - this leads to rapid recurrence 6
5. Do not intervene aggressively for manometric EGJOO without confirming clinical relevance with TBE or FLIP 2, 3